Product Categories

Industry News

Parker Institute, Cancer Research Institute team up on neoantigen-based cancer vaccines;

Researchers at 30 prestigious groups are coming together under a collaboration between the legacy Cancer Research Institute and tech billionaire Sean Parker’s new Parker Institute for Cancer Immunotherapy. Their goal? To advance development of personalized cancer vaccines based on neoantigens......................... 

Greater efforts are needed to encourage patients to report adverse drug reactions;

In a review of published studies addressing patients' perceptions and factors influencing their reporting of adverse drug reactions, most patients were not aware of reporting systems and others were confused about reporting........................ 

Lupin launches Amabelz tablets in US market;

The company's product is indicated in a woman with a uterus for treatment of moderate to severe vasomotor symptoms due to menopause and prevention of postmenopausal osteoporosis....................... 

FDA to crack whip on pharma companies;

The Food and Drug Administration (FDA), Nashik has decided to go tough on pharmaceutical companies....................... 

Eisai kicks off mid-stage study of sleep drug;

ISWRD is a circadian rhythm sleep disorder characterised by an irregular sleep-wake pattern, with patients experiencing multiple naps during the daytime but then fragmented and shortened sleep during the night....................... 

Using the freshest blood for transfusions does not appear to boost patient survival, a new Canadian study indicates.;

Old Blood as Good as New for Transfusions, Study Finds...................... 

FDA Grants Accelerated Approval to Lartruvo (olaratumab) for Advanced Soft Tissue Sarcoma;

The U.S. Food and Drug Administration today granted accelerated approval to Lartruvo (olaratumab) with doxorubicin to treat adults with certain types of soft tissue sarcoma (STS)...................... 

Chinese API makers look to move up the value chain;

China’s pharma industry is best known for being the low-cost generic API producer to the world. But companies there, large and small, are looking for ways to move up the value chain, including doing deals targeted at the U.S. market................... 

Sanofi grabs $43M in U.S. government funds to advance Zika vaccine into Phase II;

Just months after signing on with the Walter Reed Army Institute of Research to develop a Zika vaccine, Sanofi Pasteur won a $43 million vote of confidence from the U.S. government’s BARDA to advance the work.................. 

Power Grid, Pidilite, Bharat Financial, Aurobindo Pharma.;

The stock has given a fresh breakout on daily, weekly and monthly chart as managed to hit its record life time high levels................. 

Now, a paper-based device can spot poor-quality medicines;

Scientists have developed a simple, inexpensive paper-based device which can identify poor-quality or degraded medications within minutes................. 

HarlePhil Ventures to market Biocept's liquid biopsy tests in Philippines;

Biocept, Inc, a molecular diagnostics company commercializing and developing blood-based liquid biopsies to provide information to physicians to improve the diagnosis and treatment of cancer, announced a preferred provider agreement with HarlePhil Ventures, Inc.,.............. 

Cipla appoints Kedar Upadhye as global CFO;

Cipla Ltd, a global pharmaceutical company, has announced the appointment of Kedar Upadhye as the global chief financial officer of the company effective August 1, 2016.............. 

FMC elects current director as new vice president >

PHILADELPHIA, US: FMC Corporation (FMC) said that it has elected Amy O'Shea, recently appointed as business director for North America Crop for FMC Agricultural Solutions as its vice president of FMC.............. 

GlobalData expects IPF market to more than treble to $3.2bn by 2025 >

Research and consulting firm GlobalData expects that the idiopathic pulmonary fibrosis (IPF) market will increase to $3.2bn by 2025 from just more than $900m in 2015............. 

Merck, a leading science and technology company, announced today that the company has entered into an agreement with HAPPYneuron, >

Boehringer Ingelheim increases access to the medication for the treatment of HIV/AIDS............ 

Jubilant Life Sciences has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (US FDA) for Rizatriptan Benzoate Orally Disintegrating Tablets, 5 mg and 10 mg, the generic version of Maxalt-MLT Orally Disintegrating, 5 mg and 10 mg Tablets (of Merck), which is indicated for the acute treatment of migraine in adults and in pediatric patients;

Boehringer Ingelheim is announcing an expansion of its Intellectual Property (IP) enforcement policy. The IP enforcement policy had already been amended in 2007 by an easy-to-use, non-assert declaration for Viramune® (nevirapine)............ 

Jubilant Life Sciences has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (US FDA) for Rizatriptan Benzoate Orally Disintegrating Tablets, 5 mg and 10 mg, the generic version of Maxalt-MLT Orally Disintegrating, 5 mg and 10 mg Tablets (of Merck), which is indicated for the acute treatment of migraine in adults and in pediatric patients;

Boehringer Ingelheim is announcing an expansion of its Intellectual Property (IP) enforcement policy. The IP enforcement policy had already been amended in 2007 by an easy-to-use, non-assert declaration for Viramune® (nevirapine)............ 

Keytruda, developed by Schering Plough / Merck and Co, and Opdivo, developed by Ono / Bristol-Myers Squibb, are estimated to account for 50% of the global immuno-oncology market by 2024, estimates a report from GlobalData......... 

GlaxoSmithKline (GSK) has agreed to acquire Bristol-Myers Squibb's (BMS) pipeline of research and development (R&D) HIV assetsfor about $1.5bn;

 

Teva wins approval for COPAXONE to prevent relapse of multiple sclerosis............ 

 

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Teva Pharmaceutical Industries' once-daily COPAXONE (glatiramer acetate injection) 20mg injection for the prevention of relapse of multiple sclerosis;

rs Squibb's HIV assets............ 

 

 

 

Bristol-Myers Squibb announced that the National Institute for Health and Care Excellence (NICE) has recommended Daklinza (daclatasvir) in England and Wales for the treatment of adult patients with chronic hepatitis C virus (HCV) infection;

Jubilant Life Sciences wins ANDA approval for Rizatriptan Benzoate OD Tablets............ 

Jubilant Life Sciences has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (US FDA) for Rizatriptan Benzoate Orally Disintegrating Tablets, 5 mg and 10 mg, the generic version of Maxalt-MLT Orally Disintegrating, 5 mg and 10 mg Tablets (of Merck), which is indicated for the acute treatment of migraine in adults and in pediatric patients;

FDA approves Merrimack’s metastatic pancreatic cancer drug............ 

The US Food and Drug Administration (FDA) has approved Merrimack Pharmaceuticals’ metastatic pancreatic cancer drug, Onivyde;

UK launches largest trial to assess whether aspirin can fight cancer............ 

The world's largest clinical trial to see whether taking a daily dose of aspirin can stop cancer from recurring has been launched in the UK;

Pfizer-Allergan megamerger report prompts speculation about fallout for CROs............ 

Reports Pfizer is considering buying Allergan to create a company worth $330bn have once again raised fears of disruption for contract research organisations (CRO), although there are reasons to think the deal would be less troublesome than earlier megamergers;

Hanson, Shimadzu combine technologies to create an automated testing system............ 

Hanson Research and Shimadzu have teamed up to combine their respective technologies into an automated online pharmaceutical testing system;

hVIVO invests in PrEP Biopharm............ 

hVIVO has made an investment in the UK-based start-up, PrEP Biopharm, to further develop new prophylactic treatment for respiratory infections;

Tara Immuno-Oncology acquires licenses to develop clinical stage p53MVA oncology vaccine............ 

Tara Immuno-Oncology has acquired licenses from City of Hope for the development of p53MVA (modified vaccinia ankara) and a Salmonella-based therapy targeting Indoleamine 2,3-Dioxygenase (shIDO-ST), both for multiple oncology indication;

p>FDA approves Gilead Sciences' Genvoya HIV drug............ 

 

The US Food and Drug Administration (FDA) has approved Gilead Sciences' Genvoya HIV drug to treat patients aged 12 and above;

LEO Pharma to buy Astellas Pharma's global dermatology portfolio............ 

LEO Pharma has agreed to acquire Astellas Pharma's global dermatology business for €675m;

Emerson, GE Healthcare partner to increase biopharma manufacturing efficiency............ 

Emerson Process Management has partnered with GE Healthcare’s Life Sciences business to increase productivity and improve efficiency in the production of biopharmaceuticals;

AstraZeneca agrees to sell US rights for Entocort drug to Perrigo............ 

AstraZeneca has agreed to sell the US rights for its gastrointestinal drug Entocort to Perrigo for $380m;

Acquired Sigma-Aldrich businesses part of Merck's Africa growth plan............ 

New acquisition Sigma Aldrich will play a part in African growth plans in addition to giving it a presence in the preclinical services sector says Merck;

Drug Reference Standards| Deuterium Labeled Compounds

Online Product Assistant

  Search By - Product name Cas No Formula
About Us

Welcome to VIVAN Life Sciences

VIVAN Life Sciences is a Knowledge based and technology driven innovative Global Enterprise, offering higher end products in Pharmaceuticals and Life Sciences.

We provide break through collaboration for the niche pharmaceutical products, which enhance the capability and productivity performances of our customers and Business Associates around the world, In specific functions critical to their success.

Our Esteemed Clientele consists of, Global Pharmaceuticals and Life Sciences Companies, Pharmaceutical Generic companies, CROs (Contract Research Organizations), Clinical Research, Speciality Chemical Companies, Medical Research Organizations, world renowned Research Institutes and Universities.

We are instrumental in providing the higher-end products to our clientele around the world, and played an important role in the success of their Crucial projects.
there by improving and deriving exceptional value to the Projects critical to their success.

   

 

 

 




Please visit VIVAN BLOG:

  • To know the latest Industry News and Information.
  • Updates on technological evolutions in Pharma & Life Sciences.
  • Interesting story snippets for better contextual  understanding.
  • Short stories on Management & Leadership.
  • Last but not the least, We welcome your participation.
  • This certainly helps us to better the content sharing on VIVAN BLOG
Loading...
Loading...
Loading...
Loading...
Loading...